Business context and reporting period
The supplied filing is Spherix Incorporated’s Form 10-K for the fiscal year ended December 31, 2011, filed March 29, 2012. It describes two segments: Health Sciences, a technical and regulatory consulting business, and Biospherics, a pharmaceutical research and development business. The request metadata names Dominari Holdings Inc.; that does not match the issuer identified in the filing. This is an annual report, not a standalone Q4 report.
Financial performance and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $820,925 | $1,432,452 |
| Operating loss | $4,346,871 | $8,011,459 |
| Net loss | $3,461,640 | $7,736,242 |
| Net loss per share, basic and diluted | $1.32 | $4.28 |
| Net cash used in operating activities | $4,359,660 | $8,693,195 |
| Cash and cash equivalents at year-end | $4,911,350 | $5,575,310 |
| Working capital | $4.6 million | Not clearly provided |
| Total liabilities | $940,357 | $2,576,853 |
Revenue was entirely attributable to Health Sciences in 2011. Its segment operating income was $156,000, or 19% of segment revenue, compared with $464,000, or 33%, in 2010. The consolidated operating loss was approximately 530% of revenue in 2011 versus 559% in 2010. The balance sheet lists no interest-bearing debt; it does include lease and other liabilities.
Material changes versus 2010
- Revenue declined about 43%, reflecting lower effective consulting rates and staff time redirected to company R&D; Health Sciences served 20 clients versus 23.
- Research and development expense fell to $1.65 million from $4.85 million as development shifted from late-stage diabetes trials to earlier preclinical work on triglycerides and dyslipidemias.
- SG&A decreased 23% to $3.13 million, mainly after scaling back diabetes business-development spending.
- Net loss improved to $3.46 million from $7.74 million, including $845,000 in 2011 settlement gains: $600,000 related to a supplier obligation and $245,000 from settling former founders’ compensation obligations.
- Operating cash use improved to $4.36 million from $8.69 million. Financing provided $3.70 million in 2011, primarily from common-stock offerings. Cash declined by $664,000 during the year.
Outlook, commentary, risks, and unusual items
- Management expected approximately $5 million of spending over the next 12 months for planned development and operations. It believed year-end cash plus approximately $1.1 million net proceeds from a February 2012 offering would support operations through 2012; further financing would be needed to continue afterward.
- SPX-106T, a combination of D-tagatose and licensed compound SPX-106, was in animal studies. The company said an initial human efficacy study could begin in mid-2012. It estimated three or more years to generate proof of concept sufficient to seek a pharmaceutical partner, with another two to four years potentially needed for studies toward an NDA filing.
- The company had not secured a partner for D-tagatose diabetes development and had stopped spending significant resources seeking one. It reported that relevant patents had expired. A pending patent application covered triglyceride and dyslipidemia uses.
- Management cited substantial development and regulatory uncertainty, dependence on the University of Kentucky Research Foundation license and third-party manufacturers, customer concentration, and the need for additional capital. It warned that inability to raise funds could force it to stop development and dissolve. Equity financing could dilute shareholders.
- Four customers represented 20%, 15%, 12% and 11% of 2011 revenue. The company also reported that its share price was below Nasdaq’s $1 minimum bid requirement, creating delisting risk.
- After year-end, the company raised approximately $1.15 million gross in a February 2012 stock-and-warrant offering. It also amended its office lease in March 2012, extending it through March 31, 2018.
- Independent auditors issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the issuer: the filing is for Spherix Incorporated, not Dominari Holdings Inc.
- Review subsequent cash burn, financing needs, and whether the February 2012 proceeds and management’s 2012 liquidity assessment proved sufficient.
- Check progress and results of SPX-106T preclinical and human studies, IND status, partner discussions, and continuing compliance with the UKRF license.
- Assess consulting revenue concentration, customer retention, receivable collectability, and whether backlog converts to revenue; contracts may be terminated or delayed.
- Verify Nasdaq listing compliance and the potential dilution from outstanding warrants, options, and future equity offerings.
- Review the full financial statements and notes for the terms of obligations, lease commitments, settlement accounting, and any material developments after the filing date.